Two-Dimensional Electrophoresis Gel

二维电泳凝胶

• 批准号: 6550186
• 负责人: GEORGE T LEKA
• 金额: $ 8.92万
• 依托单位: JULE BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-15 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6550186
• 关键词: SDS polyacrylamide gel electrophoresis; biomedical equipment development; biotechnology; gel electrophoresis; proteomics

DESCRIPTION (provided by applicant): Since its introduction over twenty years ago, two dimensional (2D) polyacrylamide gel electrophoresis remains the most powerful and, most under-utilized approach to purifying the quantities of proteins needed for identification and structural characterization. Although virtually any application one could imagine for 1D SDS PAGE would benefit from the nearly two orders of magnitude increase in resolution provided by the second dimension, few laboratories routinely utilize 2D gel electrophoresis. The reason is that techniques and equipment for carrying out this procedure are so cumbersome and require such a high level of expertise that the majority of scientists are dissuaded from trying to master this technique. To unleash the power of 2D gel electrophoresis on a wide array of biochemical and biomedical problems we have designed a pre-cast, integral 2D gel system whose hallmark is ease of use. With the advent of the post genome era for Haemophilus lnfluenzae and twelve other micro-organisms and with the rapid progress being made on the human and greater than fifty other genomes, the opportunity for utilizing 2D gel electrophoresis to understand the proteome and human disease have never been greater and, if this application is funded, will never have been within closer reach.

描述（由申请人提供）：自二十多年前引入以来，二维（2D）聚丙烯酰胺凝胶电泳仍然是纯化鉴定和结构表征所需蛋白质量的最有效和最未充分利用的方法。尽管人们可以想象的1D SDS PAGE的几乎任何应用都将受益于第二维提供的分辨率的近两个数量级的增加，但很少有实验室常规使用2D凝胶电泳。原因是，进行这一程序的技术和设备是如此繁琐，需要如此高水平的专业知识，以至于大多数科学家都不愿尝试掌握这一技术。为了释放2D凝胶电泳在各种生物化学和生物医学问题上的力量，我们设计了一个预制的整体2D凝胶系统，其特点是易于使用。随着流感嗜血杆菌和其他12种微生物的后基因组时代的到来，以及人类和超过50种其他基因组的快速进展，利用2D凝胶电泳来了解蛋白质组和人类疾病的机会从未如此之大，如果这项应用得到资助，将永远不会更接近。